ACADIA Pharmaceuticals Future Growth
Future criteria checks 5/6
ACADIA Pharmaceuticals is forecast to grow earnings and revenue by 41.6% and 10.4% per annum respectively. EPS is expected to grow by 40.2% per annum. Return on equity is forecast to be 31.3% in 3 years.
Key information
41.6%
Earnings growth rate
40.2%
EPS growth rate
| Biotechs earnings growth | 29.1% |
| Revenue growth rate | 10.4% |
| Future return on equity | 31.3% |
| Analyst coverage | Good |
| Last updated | 08 Aug 2024 |
Recent future growth updates
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Recent updates
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
Jun 29Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In Growth
May 07Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,168 | 277 | 285 | 351 | 16 |
| 12/31/2025 | 1,055 | 157 | 143 | 209 | 20 |
| 12/31/2024 | 953 | 89 | 138 | 237 | 20 |
| 6/30/2024 | 891 | 31 | 80 | 81 | N/A |
| 3/31/2024 | 814 | -2 | 24 | 64 | N/A |
| 12/31/2023 | 726 | -61 | -23 | 17 | N/A |
| 9/30/2023 | 632 | -149 | -133 | -93 | N/A |
| 6/30/2023 | 551 | -111 | -74 | -34 | N/A |
| 3/31/2023 | 520 | -146 | -56 | -56 | N/A |
| 12/31/2022 | 517 | -216 | -114 | -114 | N/A |
| 9/30/2022 | 512 | -217 | -113 | -113 | N/A |
| 6/30/2022 | 512 | -205 | -130 | -130 | N/A |
| 3/31/2022 | 493 | -214 | -142 | -142 | N/A |
| 12/31/2021 | 484 | -168 | -127 | -126 | N/A |
| 9/30/2021 | 474 | -192 | -133 | -130 | N/A |
| 6/30/2021 | 463 | -262 | -141 | -136 | N/A |
| 3/31/2021 | 458 | -260 | -155 | -147 | N/A |
| 12/31/2020 | 442 | -282 | -144 | -136 | N/A |
| 9/30/2020 | 419 | -268 | -144 | -138 | N/A |
| 6/30/2020 | 393 | -225 | -139 | -134 | N/A |
| 3/31/2020 | 366 | -238 | -137 | -136 | N/A |
| 12/31/2019 | 339 | -235 | -152 | -151 | N/A |
| 9/30/2019 | 300 | -248 | -162 | -161 | N/A |
| 6/30/2019 | 264 | -268 | -186 | -184 | N/A |
| 3/31/2019 | 238 | -276 | -189 | -186 | N/A |
| 12/31/2018 | 224 | -245 | -170 | -167 | N/A |
| 9/30/2018 | 208 | -249 | -160 | -158 | N/A |
| 6/30/2018 | 185 | -252 | -175 | -174 | N/A |
| 3/31/2018 | 158 | -256 | N/A | -192 | N/A |
| 12/31/2017 | 125 | -289 | N/A | -218 | N/A |
| 9/30/2017 | 93 | -299 | N/A | -251 | N/A |
| 6/30/2017 | 63 | -306 | N/A | -242 | N/A |
| 3/31/2017 | 33 | -309 | N/A | -240 | N/A |
| 12/31/2016 | 17 | -271 | N/A | -208 | N/A |
| 9/30/2016 | 5 | -238 | N/A | -182 | N/A |
| 6/30/2016 | 0 | -206 | N/A | -165 | N/A |
| 3/31/2016 | 0 | -174 | N/A | -138 | N/A |
| 12/31/2015 | 0 | -164 | N/A | -122 | N/A |
| 9/30/2015 | 0 | -147 | N/A | -105 | N/A |
| 6/30/2015 | 0 | -133 | N/A | -91 | N/A |
| 3/31/2015 | 0 | -115 | N/A | -78 | N/A |
| 12/31/2014 | 0 | -92 | N/A | -66 | N/A |
| 9/30/2014 | 0 | -76 | N/A | -59 | N/A |
| 6/30/2014 | 0 | -62 | N/A | -51 | N/A |
| 3/31/2014 | 1 | -50 | N/A | -39 | N/A |
| 12/31/2013 | 1 | -38 | N/A | -32 | N/A |
| 9/30/2013 | 1 | -33 | N/A | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACAD's forecast earnings growth (41.6% per year) is above the savings rate (2.5%).
Earnings vs Market: ACAD's earnings (41.6% per year) are forecast to grow faster than the US market (14.7% per year).
High Growth Earnings: ACAD's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ACAD's revenue (10.4% per year) is forecast to grow faster than the US market (8.5% per year).
High Growth Revenue: ACAD's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACAD's Return on Equity is forecast to be high in 3 years time (31.3%)